Dr Paul Nathan is a Consultant Medical Oncologist based at The Mount Vernon Cancer Centre, in Northwood, Middlesex.

Dr Nathan received his first medical degree from Cambridge University and qualified in medicine at University College London, both achieved after earlier degrees (including a PhD) specialising in immunology. He was a Fulbright Scholar and carried out his post-doctoral research at the Pittsburgh Cancer Institute in the US. He initially pursued cancer research in academia and in the pharmaceutical industry before finally deciding to pursue a clinical career.

Dr Nathan has a specialist interest in the treatment of renal cell carcinoma (kidney cancer) and melanoma (both uveal and cutaneous).  He also has an interest in Merkel Cell Carcinoma.

He is first author of the UK guidelines for the systemic treatment of renal cell carcinoma, a member of the National Cancer Research Institute groups for both renal carcinoma and melanoma and is secretary of the UK Melanoma Study Group. He also is a member of the panel currently reviewing the national melanoma guidelines.

Professor Paul Ellis is Professor of Cancer Medicine based at King’s College London and Consultant Medical Oncologist at Guy’s & St Thomas’ Hospital.

Prof Ellis has responsibility for the management of breast cancer.

He studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and postgraduate research degree at the Royal Marsden Hospital in London. He took up his present post in 1997 and has held a number of senior management roles since then including Head of Medical Oncology at Guy’s & St Thomas’, Medical Director for the South East London Cancer Network (SELCN) and Head of Breast Cancer Clinical Research for Guy’s & St Thomas’ and the KCL Division of Cancer Medicine.

He is the author of over 100 peer reviewed scientific papers in the breast cancer field, and has been on the Editorial Board of a number of Oncology Journals including Journal of Clinical Oncology. His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of novel therapies. He was involved in chairing the UK Dept of Health Advisory committee on the introduction of Herceptin into UK clinical practice, and co-authouring the national guidelines on Herceptin use.

Professor Ellis was the principal investigator and co-chair of the trial management group for the UK National Adjuvant Chemotherapy (TACT) Trial and has been involved on the Steering Committees of numerous other clinical trials of novel anti-cancer therapies including being Co-PI on the MARIANNE and KAMILLA trials. He continues to take an active leadership role within the UK and European Clinical Trials community.

Over the last 5 years he has been actively involved in the development and growth of the Sarah Cannon Research Centre in London. He has taken a leadership role in the breast programme and links closely with Sarah Cannon in Nashville and the other centres in the US.

Dr Mark Harries is a Consultant Medical Oncologist based at Guy’s & St Thomas’ Hospitals NHS Foundation Trust and honorary senior lecturer at Kings College London School of Medicine.

Dr Harries specialises in the treatment of Breast Cancer and Melanoma.

Mark graduated from Cambridge University and underwent clinical training at The Royal London Hospital. He trained in Medical Oncology at the Royal Marsden Hospital and completed a PhD and post-doctoral work in the Department of Immunology at University College London.

Dr Harries is a member of the Association of Cancer Physicians, Royal College of Physicians, American Society of Clinical Oncology, European Society of Medical Oncology and the British Medical Association.

Dr Majid Kazmi is a Consultant Haematologist based at Guy’s & St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust.

Dr Kazmi qualified from the University of Aberdeen in 1991 with Commendation. He has been a consultant in Haemato-oncology since 2001. 

Currently Dr Kazmi is the Lead Cancer Clinician and Clinical Director of Oncology & Haematology at Guy’s & St Thomas’.  He is also medical director for commercial activities at the Trust. He is Chair of the Haemato-oncology pathway group on behalf of the London Cancer Alliance covering the population of South London and NW London (5 million people).

His clinical interests include Myeloma where he has been the UK Chief Investigator for a number of national and international studies. He sits on the UK guidelines group for Myeloma and Amyloidosis. He has extensive experience in Transplantation and is the UK lead for transplantation in auto-immune diseases for EBMT (European Group for Blood and Marrow Transplantation).

Dr Kazmi is a member of European group for Blood and Marrow Transplantation (EBMT) and American Society of Haematology (ASH), American Society of Haematology, British Society of Marrow Transplantation and the European Group for Blood and Marrow transplantation.

Dr Lucy Brazil is a Consultant Clinical Oncologist based at Guy's and St Thomas' NHS Foundation Trust.

Dr Brazl has a special interest in neuro-oncology, in particular, the treatment of glioblastoma multiforme and low grade glioma (including oligodendroglioma). She trained in oncology at Royal Marsden Hospital and Guy's and St Thomas’ Hospitals. She was awarded an MD in 2007 for research into breast cancer genetics at the Institue of Cancer Research and Breakthrough Breast Cancer. 

Dr Brazil is an active member of The National Cancer Institute Brain Tumour Clinical Studies Group, as well as The European Organisation for Research and Treatment of Cancer Brain Tumour Group. She is also Chairman of The Brain Tumour Palliative Care / Quality of Life subgroup.

Dr Brazil was Chief investigator for the CODEL brain tumour study using chemotherapy and radiotherapy for Gliomas,

Chairman of the brain tumour Palliative care QOL sub-group, and Systemic Chemotherapy Neuro-oncology Research lead at Guy’s and St Thomas’.

Professor Justin Stebbing is a Consultant Medical Oncologist based at Imperial College Healthcare NHS Trust in London.

Professor Stebbing trained in medicine at Trinity College Oxford, where he gained a triple first class degree. After completion of junior doctor posts in Oxford, he undertook a residency at The Johns Hopkins Hospital in the US, returning to London to continue his training in oncology at The Royal Marsden and St Bartholomew’s Hospitals. Professor Stebbing’s PhD research investigated the interplay between the immune system and cancer.

Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing for national newspapers and presenting new data on optimal cancer therapies at major international conferences. His focus is on new therapies in cancer, and the systemic management of patients with a variety of solid malignancies, including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery.

He is a member of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of five biotechnology companies. He chairs the World Vaccine Congress and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and Oncogene and writes BMA guidelines for several cancers.

Professor Jonathan Waxman is Professor of Oncology at Imperial College London.

Prof Waxman practises as a general oncologist, treating patients with a wide range of malignancies. He specialises in urological oncology treating patients with prostate, kidney, bladder and testicular cancer and has developed new treatments for these conditions such as LHRH agonist therapy for prostate cancer.

He helped establish an All Party Parliamentary Group to improve cancer treatment and rationalise cancer research throughout the UK and has developed and led successful media campaigns to rationalise cancer treatments and change government health policy.

He has had many years experience in Medico-Legal work providing expert reports to plantiff and defendant and appearing as an expert witness. He  has written a textbook of medical law and many medical textbook and research papers. Professor Waxman has written around 400 scientific research papers and chapters and 11 books on cancer.

Professor Jamie Cavenagh is a Professor of Haematology based at Barts Health NHS Trust.

Prof Cavenagh qualified with MB BS in 1985 from St Marys Hospital Medical School, London. He trained in clinical haematology at St Georges Hospital, The Royal Marsden Hospital and Barts and The London. 

Professor Cavenagh was a Leukaemia Research Fund Scientific Training Fellow from 1992-1994 and he is currently the Chairman of the UK Myeloma Forum.

Dr James Mackay is a Consultant Clinical Genetic Oncologist based in London.

Dr Mackay trained as a Medical Oncologist at Trinity College, Cambridge and the University of Edinburgh Medical School.  He is the only accredited Medical Oncologist in the UK with a special interest in Cancer Genetics.

Dr Mackay set up the first regular remote cancer genetics service in the world based at Great Ormond Street Hospital, conducting real time consultations with patients and their families in several peripheral London hospitals using high quality tele-conferencing technology.

Dr Hendrik-Tobias Arkenau is Medical Director at Sarah Cannon Research UK in London.

Dr Arkenau received his medical and postgraduate degree at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before being appointed as, he was Senior Clinical Fellow at the Royal Marsden Hospital and team leader for Early Drug Development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

He has obtained ASCO, AACR and ESMO Merit Awards and languages spoken are English and German